Promoters for Glaucoma Gene Therapy
About the Research Project
Program
Award Type
Standard
Award Amount
$49,986
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999005
Summary
Gene therapy may prove to be an ideal form of treatment for diseases with genetic causes because a normal version of a gene could be introduced into cells to restore functions that have been disrupted due to the genetic mutation. If gene therapy is to be used one day for treating forms of glaucoma, two requirements must be met. First, one needs an efficient means, or vector, for placing genes in eye tissues. Second, genetic elements called promoters are required that will allow the therapeutic gene to be specifically turned on in the appropriate cell type (e.g. TM cells). Dr. Brandt has already attained the first goal and is now focused on identifying TM cell-specific promoters.
Grants
Related Grants
National Glaucoma Research
Saving Sight: A Journey to Healing Without Scars
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Jennifer Fan Gaskin, FRANZCO
Saving Sight: A Journey to Healing Without Scars
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Jennifer Fan Gaskin, FRANZCO
National Glaucoma Research
IOP-Related Gene Responses in the Optic Nerve Head and Trabecular Meshwork
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Diana C. Lozano, PhD
IOP-Related Gene Responses in the Optic Nerve Head and Trabecular Meshwork
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Diana C. Lozano, PhD
National Glaucoma Research
The Impact of Glaucoma on Light-Mediated Mood and Sleep Disorders
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Xiaorong Liu, PhD
The Impact of Glaucoma on Light-Mediated Mood and Sleep Disorders
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Xiaorong Liu, PhD